AMBUCETAMIDE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H28N2O2
Molecular Weight	292.4164
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCN(CCCC)C(C(N)=O)C1=CC=C(OC)C=C1

InChI

InChIKey=WUSAVCGXMSWMQM-UHFFFAOYSA-N

InChI=1S/C17H28N2O2/c1-4-6-12-19(13-7-5-2)16(17(18)20)14-8-10-15(21-3)11-9-14/h8-11,16H,4-7,12-13H2,1-3H3,(H2,18,20)

HIDE SMILES / InChI

Molecular Formula	C17H28N2O2
Molecular Weight	292.4164
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(03)15357-3.pdf | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC286262/

Ambucetamide is an antispasmodic found to be particularly effective for the relief of menstrual pain. It was given the number R 5. Launched in April 1955 under the brand name Neomeritine, it is still on the market today.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Menstrual pain 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13491452 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC286262/	Palliative		Approved 8429	Neomeritine Approved Use An antispasmodic found to be particularly effective for the relief of menstrual pain. Launch Date 1955

PubMed

Title	Date	PubMed
Studies with a uterine antispasmodic, ambucetamide.	1957 Sep	13491452
The effects of ambucetamide on human myometrial and other preparations, and its antagonism to the menstrual stimulant.	1960 Mar	14432761
Rapid spectrophotometric determination of saccharin in soft drinks and pharmaceuticals using Azure B as reagent.	1983 Aug	6638528
Determination of embutramide in biological matrices by gas chromatography with nitrogen-phosphorus detection.	1994 Nov 4	7866553

Patents

Sample Use Guides

In Vivo Use Guide

Dogs: In general, doses of 1.0 to 10.0 mg/Kg of ambucetamide produced a drop in tone in the majority of the animals and had no effect upon the frequency of contractions. In about 50% of the dogs there was an increase in the amplitude of contractions at doses of 1.0 and 5.0 mg/Kg, but at a dose of 10.0 mg/Kg the majority showed a decrease in the amplitude of contractions.

Route of Administration: Oral

In Vitro Use Guide

Ambucetamide produced a decrease in the amplitude of contraction starting in most instances at a bath concentration of 0.025 mg/cc. This effect was quite marked at a concentration of 0.05 mg/cc. It produced a marked decrease in the frequency of contractions starting with a bath concentration of 0.125 mg/cc. No decrease in tone was noted at concentrations less than 0.025 mg/cc.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:57:57 GMT 2023` Edited by `admin` on `Sat Dec 16 17:57:57 GMT 2023`
Record UNII	131B408RZI
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AMBUCETAMIDE

Official Name

English

(±)-AMBUCETAMIDE

Common Name

English

A-16

Code

English

AMBUCETAMIDE [MART.]

Common Name

English

ambucetamide [INN]

Common Name

English

AMBUCETAMIDE, (±)-

Common Name

English

Ambucetamide [WHO-DD]

Common Name

English

AMBUCETAMIDE [MI]

Common Name

English

2-(DIBUTYLAMINO)-2-(P-METHOXYPHENYL)ACETAMIDE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29698